Literature DB >> 20585113

Different classes of antibiotics differentially influence shiga toxin production.

Colleen Marie McGannon1, Cynthia Ann Fuller, Alison Ann Weiss.   

Abstract

Shiga toxin (Stx) in Escherichia coli O157:H7 is encoded as a late gene product by temperate bacteriophage integrated into the chromosome. Phage late genes, including stx, are silent in the lysogenic state. However, stress signals, including some induced by antibiotics, trigger the phage to enter the lytic cycle, and phage replication and Stx production occur concurrently. In addition to the Stx produced by O157:H7, phage produced by O157:H7 can infect harmless intestinal E. coli and recruit them to produce Shiga toxin. To understand how antibiotics influence Stx production, Stx lysogens were treated with different classes of antibiotics in the presence or absence of phage-sensitive E. coli, and Stx-mediated inhibition of protein synthesis was monitored using luciferase-expressing Vero cells. Growth-inhibitory levels of antibiotics suppressed Stx production. Subinhibitory levels of antibiotics that target DNA synthesis, including ciprofloxacin (CIP) and trimethoprim-sulfamethoxazole, increased Stx production, while antibiotics that target the cell wall, transcription, or translation did not. More Stx was produced when E. coli O157:H7 was incubated in the presence of phage-sensitive E. coli than when grown as a pure culture. Remarkably, very high levels of Stx were detected even when growth of O157:H7 was completely suppressed by CIP. In contrast, azithromycin significantly reduced Stx levels even when O157:H7 viability remained high.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20585113      PMCID: PMC2935008          DOI: 10.1128/AAC.01783-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Isogenic lysogens of diverse shiga toxin 2-encoding bacteriophages produce markedly different amounts of shiga toxin.

Authors:  P L Wagner; D W Acheson; M K Waldor
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Shiga toxin 2-converting bacteriophages associated with clonal variability in Escherichia coli O157:H7 strains of human origin isolated from a single outbreak.

Authors:  Maite Muniesa; Mercè de Simon; Guillem Prats; Dolors Ferrer; Helena Pañella; Juan Jofre
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

3.  Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors.

Authors:  Malene Gantzhorn Pedersen; Claus Hansen; Erik Riise; Søren Persson; Katharina E P Olsen
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

4.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

5.  Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice.

Authors:  X Zhang; A D McDaniel; L E Wolf; G T Keusch; M K Waldor; D W Acheson
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

6.  Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro.

Authors:  J Murakami; K Kishi; K Hirai; K Hiramatsu; T Yamasaki; M Nasu
Journal:  Int J Antimicrob Agents       Date:  2000-07       Impact factor: 5.283

7.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Authors:  Richard L Siegler; Tom G Obrig; Theodore J Pysher; Vernon L Tesh; Nathaniel D Denkers; Fletcher B Taylor
Journal:  Pediatr Nephrol       Date:  2003-01-10       Impact factor: 3.714

8.  CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings.

Authors:  Marc Steinborn; Steffen Leiz; Klaus Rüdisser; Martin Griebel; Thomas Harder; Helmut Hahn
Journal:  Pediatr Radiol       Date:  2004-07-29

9.  Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin.

Authors:  Shantini D Gamage; Jane E Strasser; Claudia L Chalk; Alison A Weiss
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

10.  Escherichia coli serogroup O107/O117 lipopolysaccharide binds and neutralizes Shiga toxin 2.

Authors:  Shantini D Gamage; Colleen M McGannon; Alison A Weiss
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

View more
  73 in total

1.  A Conserved Structural Motif Mediates Retrograde Trafficking of Shiga Toxin Types 1 and 2.

Authors:  Andrey S Selyunin; Somshuvra Mukhopadhyay
Journal:  Traffic       Date:  2015-11-02       Impact factor: 6.215

2.  Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Authors:  Joanne L Fothergill; Eilidh Mowat; Martin J Walshaw; Martin J Ledson; Chloe E James; Craig Winstanley
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

3.  Campylobacter-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome.

Authors:  Emily Elizabeth Bowen; Robert Hangartner; Iain Macdougall
Journal:  J Gen Intern Med       Date:  2015-05-23       Impact factor: 5.128

Review 4.  Taming the Beast: Interplay between Gut Small Molecules and Enteric Pathogens.

Authors:  Aman Kumar; Melissa Ellermann; Vanessa Sperandio
Journal:  Infect Immun       Date:  2019-08-21       Impact factor: 3.441

Review 5.  Competition sensing: the social side of bacterial stress responses.

Authors:  Daniel M Cornforth; Kevin R Foster
Journal:  Nat Rev Microbiol       Date:  2013-03-04       Impact factor: 60.633

Review 6.  Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence.

Authors:  Dakshina M Jandhyala; Vijay Vanguri; Erik J Boll; Yushuan Lai; Beth A McCormick; John M Leong
Journal:  Infect Dis Clin North Am       Date:  2013-07-24       Impact factor: 5.982

7.  Conserved Arginines at the P-Protein Stalk Binding Site and the Active Site Are Critical for Ribosome Interactions of Shiga Toxins but Do Not Contribute to Differences in the Affinity of the A1 Subunits for the Ribosome.

Authors:  Debaleena Basu; Jennifer N Kahn; Xiao-Ping Li; Nilgun E Tumer
Journal:  Infect Immun       Date:  2016-11-18       Impact factor: 3.441

8.  Identification of Antibiotics That Diminish Disease in a Murine Model of Enterohemorrhagic Escherichia coli Infection.

Authors:  Sabrina Mühlen; Isabell Ramming; Marina C Pils; Martin Koeppel; Jana Glaser; John Leong; Antje Flieger; Bärbel Stecher; Petra Dersch
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 9.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

10.  Coculture of Escherichia coli O157:H7 with a Nonpathogenic E. coli Strain Increases Toxin Production and Virulence in a Germfree Mouse Model.

Authors:  Kakolie Goswami; Chun Chen; Lingzi Xiaoli; Kathryn A Eaton; Edward G Dudley
Journal:  Infect Immun       Date:  2015-08-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.